Biomarker-directed therapies reshape GI cancer treatment, says expert
In a recent OncLive On Air podcast, host Courtney Flaherty spoke with Dr. Michael J. Pishvaian about the growing role of biomarker-directed strategies in gastrointestinal oncology.
Dr. Pishvaian noted a clear shift from a disease-site-specific approach toward a molecularly defined paradigm, stressing that early, comprehensive testing is essential to uncover the drivers and resistance mechanisms that influence frontline treatment choices.
He highlighted three key targets-HER2, CLDN18.2 and KRAS inhibition-as examples of how precision medicine is expanding therapeutic options for GI cancers.
The discussion underscored the importance of integrating molecular profiling into routine practice to guide treatment sequencing and improve patient outcomes.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD”
read at onclive ↗
comments(0)
5-min edit window · permanent after that